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The HMFEC trial was developed at a time of uncertainty around the dose 
intensity of chemotherapy given to premenopausal patients with node positive 
breast cancer and to the benefits of tailored endocrine therapy in such 
patients. 
Patients and methods 
HMFEC was a multi-centre, phase III, open label, randomised controlled trial 
with a 2x2 factorial design. Eligible patients were premenopausalwith node 
positive early breast cancer; significant cardiac disease or uncontrolled 
hypertension were exclusion criteria. Patients were allocated to receive either 
8 cycles of FE50C or FE75C (given 3 weekly) with or without hormone 
manipulation (HM) (tamoxifen or LHRH agonists according to residual 
hormone levels at end of chemotherapy) irrespective of ER status.  The 
primary endpoint was disease free survival (DFS). Principal analyses were by 
ITT; however, to reflect contemporary practice, subgroup analyses according 
to ER status were also conducted. The mature follow-up now available from 
this modest sized trial enables presentation of definitive results. 
Results 
Between 1992-2000 a total of 785 patients were randomised into the HMFEC 
trial (203 FE50C-HM, 191 FE50C+HM, 198 FE75C-HM, 193 FE75C+HM).At a 
median follow-up of 7.4 years, 245 DFS events have been reported (92 ER-, 
153 ER+/unknown).  The effects on DFS were not statistically significantly 
different according to epirubicin dose (HR=0.82, 95%CI: 0.63-1.06; p=0.13 





neutropenia. No statistically significant evidence was observed to support an 
improvement in DFS in patients allocated HM either overall (HR=0.88, 95%CI: 
0.68-1.13; p=0.32) or in patients with ER+/unknown disease (HR=0.85, 
95%CI: 0.62-1.17; p=0.32) although effect sizes are consistent with 
worthwhile clinical effects. Overall, there was no evidence of a difference in 
survival between any of the four treatment groups of the trial. 
Conclusion 
Higher doses of epirubicin cause more adverse events in the absence of clear 
improvement in overall survival. Endocrine therapy with either tamoxifen or 
goserelin provided no significant added benefit to cytotoxic chemotherapy in 
this group of patients. 
 








In 1990, at the inception of the HMFEC trial, there was uncertainty 
surrounding the optimal dose of anthracycline chemotherapy in patients with 
early breast cancer (EBC). Previously, Bonnadonna et al had reported the 
success of CMF in delaying recurrence (1) and early EBCTCG overview 
results had begun to characterise effects of tamoxifen and cytotoxic therapy 
on breast cancer recurrence and mortality, disclosing an unequivocal benefit 
for premenopausal patients receiving chemotherapy. At that time, the benefit 
for tamoxifen alone (i.e. without chemotherapy) was only evident in 
postmenopausal women (2). Further, the concept of substituting an 
anthracycline for methotrexate in the CMF regimen was being evaluated by 
our group, amongst others, in premenopausal patients with node positive EBC 
and early results suggested a possible benefit for FEC compared with CMF in 
terms of disease free survival (DFS) (3, 4). However, this trial, as well as 
others in the adjuvant setting (5) and experience in patients with metastatic 
breast cancer, had disclosed additional toxicity, especially cardiac toxicity (6). 
However this was largely considered to occur after relatively high cumulative 
doses of anthracyclines and more commonly with doxorubicin than with 
epirubicin. Thus, clinicians were uncertain as to the ultimate worth of 
anthracycline substitution as well as the optimal anthracycline dosage.  
 
In view of the EBCTCG 1988 meta-analysis, many clinicians argued that 
adding either tamoxifen or ovarian ablation to chemotherapy in 
premenopausal patients was both toxic and unnecessary following 





amenorrhoea, which itself could have the potential to improve survival (7). A 
study to assess the effects of adjuvant medical ovariectomy in those who had 
retained ovarian function after chemotherapy and of tamoxifen in those who 
had become amenorrhoeic was warranted. 
 
We therefore proposed to assess a 3 weekly schedule of FEC using 50mg/m2 
of epirubicin (FE50C), a standard dose at the time, versus FEC using 75mg/m
2 
of epirubicin (FE75C) followed by hormonal manipulation (HM) or not in 
premenopausal women with node positive breast carcinoma.   
 
 
Patients, material and methods 
HMFEC was a multi-centre, phase III, randomised controlled trial with a 2x2 
factorial design. Patients were randomised to either receive FE50C or FE75C 
with or without sequential HM.  To enter a patient centres faxed the ICCG 
Data Centre where randomisation was centrally and independently managed. 
Allocation utilised computer-generated permuted blocks stratified by centre 
and using a 1:1:1:1 treatment allocation. 
 
Patients with histologically confirmed invasive primary breast cancer were 
eligible if they were premenopausal (defined as either last menstrual period 
within one year of randomisation, or circulating oestrogen (E2) and FSH/LH 
levels compatible with ovarian function)and had 1-5 histologically involved 
axillary lymph nodes. Patients were to have had either mastectomy or 





had to have adequate bone marrow (WBC 3.5x109/l, platelet 
count100x109/l), renal and hepatic function (creatinine 120mol/l, bilirubin 
30mol/l), be accessible for follow-up, and have given informed consent 
according to the rules of the participating institution. Patients with significant 
cardiac disease or uncontrolled hypertension were ineligible. 
 
All treatments administered in the trial were open label.  Chemotherapy doses 
wereeither 5-fluorouracil 600mg/m2, epirubicin 50mg/m2, and 
cyclophosphamide 600mg/m2 (FE50C) or the same regimen but with epirubicin 
75mg/m2 (FE75C). The regimen was administered in three-weekly cycles for a 
total of 8 cycles. Dose modifications and/or delays for chemotherapy were 
based on treatment day haematological and liver toxicity.  Weekly blood 
counts were performed until recovery at which time chemotherapy could be 
resumed.  In addition, a 25% dose reduction for all drugs at subsequent 
cycles was recommended for unresolved mouth ulceration. Chemotherapy 
was discontinued for any patient whose nadir WBC dropped below 1.0x109/l 
or whose platelet count dropped below 25x109/l, patients who had 
appearance of congestive heart failure or persistent arrhythmia, or patients 
who had a >2 month break in treatment for any reason. 
 
HM was scheduled to start once chemotherapy had been completed. On 
completion of chemotherapy FSH/LH levels were assessed to evaluate extent 
of continuing ovarian function and thus to classify whether or not patients 
remained premenopausal (defined as persistent menstruations and/or low 





patients previously allocated HM were prescribed a long-acting GnRH agonist 
(goserelin or equivalent) given subcutaneously every 28 days for 3 years if 
they remained premenopausal and tamoxifen (20mg daily) for a total of 5 
years if they did not.  If the GnRH agonist was discontinued for any reason the 
patient was to receive tamoxifen up to the end of the planned period of 
hormonal therapy. Routine testing of hormone receptor (HR) status was not 
yet in place in centres at the time of trial initiation and thus allocation to HM 
was irrespective of HR status. 
 
The primary endpoint was DFS defined as time to local-regional recurrence, 
(ipsilateral breast or axillary node relapse), distant recurrence, new primary 
breast cancer or death from any cause; patients who remained alive and 
disease-free at their last follow-up were censored at that date. Secondary 
endpoints were breast cancer free survival (BCFS), defined as time to local-
regional recurrence, distant recurrence, new primary breast cancer or breast 
cancer death prior to confirmation of relapse; DFS using the STEEP definition 
(8); metastasis-free survival (MFS) defined as time to occurrence of 
metastases or breast cancer death prior to confirmation of relapse; and 
overall survival (OS). All time-to-event endpoints were measured from date of 
randomisation.  Where cause of death was unknown, these events were 
classed conservatively as breast cancer deaths.  Treatment-related deaths 
were classified as any death occurring within 30 days of receiving trial 






HMFEC was designed to test the effect on DFS of two separate treatment 
comparisons; FE50C versus FE75C and adjuvant chemotherapy +/- sequential 
HM.  Assuming a five year DFS of 60%, 720 patients (180 per group) would 
enable detection of an absolute difference of 10% (improvement from 60% to 
70%) with a 5% significance level and 80% power.   To allow for possible non-
compliance with follow-up, the trial aimed to recruit 800 patients.  Efficacy 
analyses were conducted using the intention-to-treat population, stratified by 
ER status and, for the chemotherapy comparison, by the HM randomisation, 
and for HM, by the chemotherapy randomisation.  Evidence subsequent to 
that available at trial initiation confirmed the restriction of hormone therapy to 
patients with ER-positive disease.  Therefore, it was agreed, a-priori, that 
patients with ER-positive or ER-negative disease would also be analysed 
separately due to the differential effect of endocrine therapy according to ER 
status and the likelihood of confounding due to different time dependent risk 
profiles for these two patient groups (i.e. ER-negative=high early risk of 
relapse, ER-positive=lower but prolonged risk of relapse).  Time to event 
analyses were conducted with Kaplan-Meier plots graphically depicting 
survival functions and log-rank tests providing a comparison between 
treatment groups. Hazard ratios (HR) were determined with Cox proportional 
hazards regression analysis both univariately and following adjustment for 
BMI, age at randomisation, nodal status, tumour grade and size with values 
<1 favouring FE75C for the chemotherapy comparison and favouring 
sequential chemotherapy+HM for the HM comparison.  This analysis includes 






Further details on Materials and Methods are available in the Supplementary 
Patients and Methods (web appendix – Data A1).  
 
Results 
Between 1992-2000 a total of 785 patients from 16 centres in 7 European 
countries (web appendix-List A1) were randomised (203 FE50C-HM, 191 
FE50C+HM, 198 FE75C-HM, 193 FE75C+HM) (web appendix-Figure A1).  The 
median observed follow-up was 7.4 years (IQR 4.8-10.1) in all surviving 
patients.  Baseline clinic-pathological characteristics of patients were evenly 
balanced between treatment groups (web-appendix-table A1). 
 
Chemotherapy compliance was good overall with 706 (89.9%) receiving all 8 
cycles of chemotherapy (FE50C=363 (92.1%), FE75C=343 (87.7%), (web 
appendix–table A2).  The principal reasons for early discontinuation were 
toxicity and patient choice. Twenty four patients (3.1%) did not start allocated 
chemotherapy (2 FE50C-HM, 5 FE50C+HM, 4 FE75C-HM, 13 FE75C+HM). 
However, of these, nine patients received alternative anthracycline treatment.  
These patients were analysed according to randomised treatment.  RDI in the 
ITT population was slightly lower in FE75C patients, with 301 (77.0%) 
receiving at least 85% of their planned dose intensity compared with 328 
(83.2%) of patients allocated FE50C. 
 
A total of 756 (96.3%) patients (365 (95.1%) allocated HM, 391 (97.5%) 
allocated no HM) completed chemotherapy treatment and remained disease-





allocated to no HM, 119 (30.4%) were classified as premenopausal post-
chemotherapy, 245 (62.7%) were postmenopausal post-chemotherapy and 27 
(6.9%) had unassessed menopausal status post-chemotherapy; for those 
allocated HM, there figures were 79 (21.6%), 275 (75.3%) and 11 (3.0%) 
respectively.  In patients allocated HM, 47 (59.5%) were prescribed GNRH 
aloneand249 (90.5%) patients received tamoxifen alone as per protocol.  47 
(12.0%) patients allocated not to receive HM received either GNRH or 
tamoxifen (web appendix-table A3).  
 
In total, 245 DFS events have been reported (FE50C=133, FE75C=112; 
HM+=114, HM-=131; ER+=153, ER-=92) (web appendix-table A4).There was 
no evidence that FE75C was significantly better than FE50C for DFS 
(HR(unadjusted)=0.83, 95%CI:0.65-1.07; p=0.15) – Figure 1a, 
(HR(adjusted)=0.82, 95%CI:0.63-1.06; p=0.13). However, the effect size for 
the improvement of DFS for FE75C was consistent with a clinically worthwhile 
effect compared with FE50C for patients with ER- disease 
(HR(unadjusted)=0.66, 95%CI:0.44-1.01; p=0.05 – Figure 1b, 
HR(adjusted)=0.71, 95%CI:0.46-1.12; p=0.14). In addition, for patients with 
ER+/unknown disease randomised to receive HM,FE75C appeared 
significantly better than FE50C in terms of DFS (HR(unadjusted)=0.59, 
95%CI:0.36-0.95; p=0.03 – Figure 1c, HR(adjusted)=0.54, 95%CI:0.32-0.89; 
p=0.02).  There was no evidence of a difference between FE50C and FE75C 
for DFS in patients with ER+/unknown disease randomised to receive no HM 
(HR(unadjusted)=1.44, 95%CI:0.93-2.23; p=0.10) – Figure 1d, HR(adjusted) 






Overall, there was no evidence of a benefit of HM for DFS 
(HR(unadjusted)=0.88, 95%CI:0.68-1.13; p=0.32)– Figure 2a, 
(HR(adjusted)=0.85, 95%CI:0.66-1.10; p=0.22), For patients with ER- disease 
the results, as now expected, suggested little effect (HR(unadjusted)=0.93, 
95%CI:0.62-1.40; p=0.72) – Figure 2b, (HR(adjusted) =1.06, 95%CI:0.69-
1.63; p=0.80) however for patients with ER+/unknown disease, the effects 
were consistent with worthwhile clinical effects (HR(unadjusted)=0.85, 
95%CI:0.62-1.17; p=0.32) – Figure 2c, (HR(adjusted) =0.74, 95%CI:0.53-
1.04; p=0.08). 
 
BCFS, DFS-STEEP and MFS show similar results to those reported for DFS 
(web appendix–table A4).   
 
At a median follow-up of 7.4 years, deaths have been reported for a total of 
131 (16.7%) patients (FE50C-HM=34, FE50C+HM=36, FE75C-HM=29, 
FE75C+HM=32).Overall, there was no evidence of a difference in survival 
between any of the four treatment groups. Thus, no difference in OS was 
seen between FE50C and FE75C (HR(unadjusted)=0.90, 95%CI:0.64-1.28; 
p=0.58 – Figure 3a).  Results are similar for the FEC dose comparison when 
considering the clinically relevant subgroups, i.e. for patients with either ER- 
disease (all ER- patients) (HR (unadjusted)=0.76, 95%CI:0.45-1.28; p=0.29 – 
Figure 3b), ER+/unknown disease (with HM) (HR=0.66, 95%CI:0.36-1.23; 
p=0.19 – Figure 3c) and ER+/unknown disease (without HM) (HR=1.96, 






Similarly, there was no evidence of a difference according to whether patients 
were prescribed HM either overall (HR=1.11, 95%CI:0.79-1.56; p=0.55 – 
Figure 4a) or specifically for those patients with ER- disease (HR=0.83, 
95%CI:0.49, 1.39; p=0.48 – Figure 4b) or ER+/unknown disease (HR=1.40, 
95%CI:0.88, 2.23; p=0.15 – Figure 4c). 
 
Four (3.1%) patients died of non-breast cancer causes in the absence of a 
reported metastatic relapse; one patient died following a pulmonary embolism 
(allocated to FE50C-HM) 3.8 years after randomisation and having received 
tamoxifen off protocol. One had a myocardial infarction (FE50C-HM) 7.9 years 
after randomisation, one died of septic shock associated with pancytopenia 
(FE75C+HM) 3.6 years after randomisation and therefore not related to 
chemotherapy allocated as part of the trial and one died from ovarian cancer 
(FE75C+HM) 10.7 years after randomisation.    
 
A total of 770 (98.1%) patients received at least one cycle of chemotherapy. 
Of the pre-specified toxicities, all but leucopenia were numerically more 
common in patients receiving FE75C compared with FE50C (web appendix-
Table A5).  However, only grade 3 and 4 alopecia was statistically significantly 
more frequently reported for FE75C (FE50C=142 (36.5%), FE75C=205 (53.8%); 
p<0.001).  In addition, the reported incidence of grade 3 and 4 neutropenia 
(non-febrile), a toxicity that was not pre-specified, was statistically significantly 









The results of this trial suggest benefit from chemotherapy in premenopausal 
patients with EBC may be increased by using a higher dose of epirubicin in 
the FEC regimen, although the improvement in DFS did not meet statistical 
significance.  Increasing anthracycline dose however, comes at the cost of 
greater toxicity, in particular, neutropenia and alopecia.  Since the initiation of 
HMFEC the adjuvant treatment of premenopausal patients with EBC has 
evolved considerably.  The recent EBCTCG meta-analyses demonstrated that 
lower doses of chemotherapy per cycle appear less effective than higher 
doses, consistent with the findings in this study.  In practice, epirubicin doses 
still vary, and while FE50C may be considered to contain an insufficient dose 
of epirubicin today, FE75C remains a commonly used regimen, often given 
followed by a taxane, following reported benefits of this sequence (9). 
Taxanes have also been evaluated as a replacement to anthracycline-
containg regimens since the initiation of our trial (10). The 2015 St Gallen 
statement on the issue of taxanes concluded that, for Luminal B-like patients 
deemed to require chemotherapy, taxanes should be considered for patients 
with more extensive disease burden, in contrast to Luminal A-like patients, 
where anthracycline regimens or CMF could be used. In triple-negative 
disease, the Panel considered that the chemotherapy should include an 
anthracycline and a taxane. (11). FEC100 has also since been shown by 
others to be more effective than FEC 50, for both DFS and overall 
survival.(12) In addition, the meta-analyses reported that, in premenopausal 
patients who had ER-positive EBC, the beneficial effect of chemotherapy 






HMFEC also looked at the effect of HM in patients following chemotherapy.  
There was no evidence to suggest that HM improved DFS in either patients 
with ER- negative or ER-positive EBC.  However, while this result is expected 
for ER-negative disease (as has been shown in another trial in which 
tamoxifen was found to be ineffective in ER negative premenopausal patients 
(13), the inconclusive result seen for ER-positive patients in this study is likely 
due to small numbers and insufficient power rather than a lack of effect of HM, 
given the recent results of large randomised trials showing the benefit of 
adjuvant endocrine therapy in these patients. (14) Recent results from the 
SOFT trial suggest that, for a subgroup of patients with ER-positive breast 
cancer who remain premenopausal post-chemotherapy, ovarian suppression 
in addition to tamoxifen reduced the risk of breast cancer recurrence 
compared with tamoxifen alone (15) and suggest this is weighted towards 
patients <35 years of age at breast cancer diagnosis.    In our study, 
analogous to this, the patients who became amenorrhoeic and subsequently 
received tamoxifen would perhaps have benefitted more than those patients 
who received goserelin alone (15).  In addition, the SOFT/TEXT trial further 
suggests that, at least in some patients, the addition of an aromatase inhibitor 
to ovarian suppression may be more efficacious than tamoxifen (14).  In 
contrast, the ABC trial, that randomised pre- and perimenopausal patients 
with EBC who were receiving five years tamoxifen treatment with or without 
chemotherapy, to ovarian ablation or suppression (OAS) versus no OAS 
concluded that OAS gave no added benefit to either tamoxifen alone or 





did not pre-select patients on the basis of them remaining premenopausal 
following chemotherapy and whereas the median age in this subgroup in 
SOFT was 40 years, less than a quarter of patients in ABC were <40 at trial 
entry. Irrespective of effects of ovarian suppression however one would 
expect to observe an improvement due to the sequential addition of 
tamoxifen.  
 
There are some aspects of this study which fall short of current practice: 
principally, the small sample size; however, at the time of study conception 
trialists often anticipated larger treatment effects explaining the smaller 
number of patients required. This deficiency is, to some extent, ameliorated 
by the long follow-up duration, a consideration which contributed to the 
delayed publication of results from this trial.  Secondly, we allocated 
endocrine therapy to ER-negative patients, who nowadays would not be 
expected to benefit from such treatment, because of uncertainty around the 
predictive ability of ER at that time (17). Finally, in patients who became 
amenorrhoeic, we assessed ovarian status by a single estimation of estradiol, 
FSH and LH; it is increasingly recognised that younger patients can regain 
ovarian function some time after the completion of chemotherapy and for this 
reason contemporary practice is to measure hormones on more than one 
occasion.  
 
In conclusion, we have observed a modest improvement in DFS in patients 
who received FE75C compared with FE50C chemotherapy, but this is 





of effect on survival, we cannot recommend the higher dose of FEC in this 
subgroup of breast cancer patients.  No conclusive benefit of additional HM 
therapy was observed, although the magnitude of effect observed was 
consistent with that seen elsewhere in the literature and it is likely that such 
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Fig. 2. a: DFS in ITT population sequential chemotherapy þ HM (HM) versus chemotherapy 
alone (No HM). b: DFS in patients with ER disease sequential chemotherapy þ HM (HM) 
versus chemotherapy alone (No HM). c:DFS in patients with ERþ/unknown disease 








Fig. 3. a: OS in ITT populationeFE50C versus FE75C. b: OS in patients with ER 
diseaseeFE50C versus FE75C. c: OS in patients with ERþ/unknown diseaseeFE50CþHM 










Fig. 4. a: OS in ITT populationesequential chemotherapy þ HM (HM) versus chemotherapy 
alone (No HM). b: OS in patients with ERþ/unknown diseaseesequential chemotherapy þ HM 
(HM) versus chemotherapy alone (No HM). c: OS in patients with ER diseaseesequential 
chemotherapy þ HM (HM) versus chemotherapy alone (No HM). 
